Emerging gonadotropin-releasing hormone agonists

Expert Opinion on Emerging Drugs

Volumn 16, Issue 2, 2011, Pages 323-340

  Beyer, Daniel Alexander ^a   Amari, Feriel ^a   Thill, Marc ^a   Schultze Mosgau, Askan ^a   Al Hasani, Safaa ^a   Diedrich, Klaus ^a   Griesinger, Georg ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

breast cancer; buserelin; fertility preservation; GnRH agonist; goserelin; leuprolide; triptorelin

Indexed keywords

AEZS 108; ANTIANDROGEN; BUSERELIN; CETRORELIX; CHLORMETHINE; CONJUGATED ESTROGEN; CYCLOPHOSPHAMIDE; DANAZOL; DOCETAXEL; EXEMESTANE; FLUOROURACIL; GANIRELIX; GESTAGEN; GESTRINONE; GONADORELIN AGONIST; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; GOSERELIN; HISTRELIN; LEUPRORELIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; NAFARELIN ACETATE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PREDNISOLONE; PROCARBAZINE; RECOMBINANT FOLLITROPIN; S 746766; TAMOXIFEN; TIBOLONE; TRIPTORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; WY 42422;

ADVANCED CANCER; AMINO ACID SEQUENCE; ANALGESIA; ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CARBOXY TERMINAL SEQUENCE; CLINICAL EFFECTIVENESS; CONSTIPATION; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG INDICATION; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; ESTROGEN SYNTHESIS; FATIGUE; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GONADOTOXICITY; GYNECOMASTIA; HODGKIN DISEASE; HOT FLUSH; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INJECTION SITE REACTION; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; MALE FERTILITY; MAXIMUM TOLERATED DOSE; MOOD DISORDER; MULTICENTER STUDY (TOPIC); OVARY CANCER; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRECOCIOUS PUBERTY; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; PRESERVATION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPERMATOGENESIS; STEROIDOGENESIS; TESTIS ATROPHY; TESTIS CANCER; TOXICITY; TRANSDERMAL PATCH; UTERUS MYOMA; VAGINAL DRYNESS; WHOLE BODY RADIATION;

ANIMALS; BREAST NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; REPRODUCTION;

EID: 79957625415     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.547472     Document Type: Review

References (107)

1. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205 (Pubitemid 27171519)
2. Stojilkovic SS, Catt KJ. Expression and signal transduction pathways of gonadotropin-releasing hormone receptors. Recent Prog Horm Res 1995;50:161-205
3. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405 (Pubitemid 24158170)
4. Borroni R, Di Blasio AM, Gaffuri B, et al. Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol 2000;159:37-43 (Pubitemid 30067638)
5. Tesone M, Vitale A, Parborell F. Gonadotropin- releasing- hormone action on ovarian steroidgenesis and apoptosis. Res Trends 1999;2:81-91
6. MacFarlane M, Williams AC. Apoptosis and disease: a life or death decision. EMBO Rep 2004;5:674-8
7. Stouffer RL, Martinez-Chequer JC, Molskness TA, et al. Regulation and action of angiogenic factors in the primate ovary. Arch Med Res 2001;32:567-75 (Pubitemid 34031749)
8. Tesone M, Bilotas M, Baranao RI, Meresman G. The role of GnRH analogues in endometriosis-associated apoptosis and angiogenesis. Gynecol Obstet Invest 2008;66:10-18
9. So WK, Cheng JC, Poon SL, Leung PC. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 2008;275:5496-511
10. Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2009;(4):CD004562 An excellent publication on GnRH agonists for adjuvant breast cancer therapy.
11. Millar RP, Lu ZL, Pawson AJ, et al. Gonadotropin-releasing hormone receptors. Endocr Rev 2004;25:235-75 (Pubitemid 38501395)
12. Yang-Feng TL, Seeburg PH, Francke U. Human luteinizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2-p21). Somat Cell Mol Genet 1986;12:95-100
13. Radovick S, Wondisford FE, Nakayama Y, et al. Isolation and characterization of the human gonadotropin-releasing hormone gene in the hypothalamus and placenta. Mol Endocrinol 1990;4:476-80
14. Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005;26:283-306
15. White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 1998;95:305-9 (Pubitemid 28103949)
16. Millar RP. GnRH II and type II GnRH receptors. Trends Endocrinol Metab 2003;14:35-43
17. Wu HM, Wang HS, Huang HY, et al. GnRH signaling in intrauterine tissues. Reproduction 2009;137:769-77
18. Cui J, Smith RG, Mount GR, et al. Identification of Phe313 of the gonadotropin-releasing hormone (GnRH) receptor as a site critical for the binding of nonpeptide GnRH antagonists. Mol Endocrinol 2000;14:671-81 (Pubitemid 32260511)
19. Bockaert J, Marin P, Dumuis A, Fagni L. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett 2003;546:65-72
20. Stanislaus D, Ponder S, Ji TH, Conn PM. Gonadotropin-releasing hormone receptor couples to multiple G proteins in rat gonadotrophs and in GGH3 cells: evidence from palmitoylation and overexpression of G proteins. Biol Reprod 1998;59:579-86 (Pubitemid 28395073)
21. Myburgh DB, Millar RP, Hapgood JP. Alanine-261 in intracellular loop III of the human gonadotropin-releasing hormone receptor is crucial for G-protein coupling and receptor internalization. Biochem J 1998;331:893-6 (Pubitemid 28211914)
22. Yano T, Yano N, Matsumi H, et al. Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development. Horm Res 1997;48(Suppl 3):35-41 (Pubitemid 27352731)
23. Imai A, Takagi A, Horibe S, et al. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab 1998;83:427-31 (Pubitemid 28496517)
24. Wang Y, Matsuo H, Kurachi O, Maruo T. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol 2002;146:447-56 (Pubitemid 34257657)
25. Oakley AE, Clifton DK, Steiner RA. Kisspeptin signaling in the brain. Endocr Rev 2009;30:713-43
26. Lee JH, Miele ME, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996;88:1731-7 (Pubitemid 26405010)
27. de Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA 2003;100:10972-6 (Pubitemid 37140137)
28. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003;349:1614-27 (Pubitemid 37303886)
29. d'Anglemont de Tassigny X, Colledge WH. The role of kisspeptin signaling in reproduction. Physiology (Bethesda) 2010;25:207-17
30. Gill JC, Wang O, Kakar S, et al. Reproductive hormone-dependent and -independent contributions to developmental changes in kisspeptin in GnRH-deficient hypogonadal mice. PLoS One 2010;5:e11911
31. Prentice LM, Klausen C, Kalloger S, et al. Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosisand clear cell subtype in ovarian carcinoma. BMC Med 2007;5:33
32. Martin TA, Watkins G, Jiang WG. KiSS-1 expression in human breast cancer. Clin Exp Metastasis 2005;22:503-11 (Pubitemid 41750702)
33. Horikoshi Y, Matsumoto H, Takatsu Y, et al. Dramatic elevation of plasma metastin concentrations in human pregnancy: metastin as a novel placenta-derived hormone in humans. J Clin Endocrinol Metab 2003;88:914-19 (Pubitemid 36207842)
34. Muir AI, Chamberlain L, Elshourbagy NA, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem 2001;276:28969-75
35. Cuzick J. Use of LHRH-agonists as adjuvant therapy for breast cancer. Expert Opin Ther Targets 2008;12:1065-71 A good review on GnRH therapy for breast cancer.
36. LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-23
37. Kaufmann M, Jonat W, Blamey R, et al. Zoladex Early Breast Cancer Research Association(ZEBRA) Trialists' Group. Survival analyses from the ZEBRA study. Goserelin(Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003;39:1711-17 (Pubitemid 36897608)
38. International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95:1833-46 A very interesting trial about node-negative patients.
39. Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008;14:543-52 An excellent review.
40. Da Silva-Buttkus P, Marcelli G, Franks S, et al. Inferring biological mechanisms from spatial analysis: prediction of a local inhibitor in the ovary. Proc Natl Acad Sci USA 2009;106:456-61
41. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045-51 (Pubitemid 46638800)
42. Schilsky RL, Sherins RJ, Hubbard SM, et al. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981;71:552-6 (Pubitemid 12140420)
43. Anderson RA, Themmen AP, Al-Qahtani A, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve inpremenopausal women with breast cancer. Hum Reprod 2006;21:2583-92 (Pubitemid 44542149)
44. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;30:465-93
45. Beyer DA, Amari F, Kavallaris A, et al. Preserving fertility in patients with malignant diseases. Current strategies. Der Onkologe 2010;10; DOI 10.1007/s00761-010-1946-z
46. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209-18
47. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001;7:535-43 (Pubitemid 33069611)
48. Mead G. The effects of cancer treatment on reproductive functions. Clin Med 2007;7:544-5 (Pubitemid 350260074)
49. Gandini L, Sgro P, Lombardo F, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod 2006;21:2882-9 (Pubitemid 44567002)
50. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005;83:1622-8
51. Rosendahl M, Andersen CY, Ernst E, et al. Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Hum Reprod 2008;23:2475-83
52. Littley MD, Shalet SM, Beardwell CG, et al. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol (Oxf) 1989;31:363-73 (Pubitemid 19219244)
53. Bath LE, Anderson RA, Critchley HO, et al. Hypothalamic-pituitary-ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia. Hum Reprod 2001;16:1838-44 (Pubitemid 32916209)
54. Donnez J, Martinez-Madrid B, Jadoul P, et al. Ovarian tissue cryopreservation and transplantation: a review. Hum Reprod Update 2006;12:519-35 (Pubitemid 44288709)
55. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004;22:4174-83 (Pubitemid 41185188)
56. Thewes B, Meiser B, Taylor A, et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 2005;23:5155-65 (Pubitemid 46224024)
57. Revel A, Schenker J. Ovarian tissue banking for cancer patients: is ovarian cortex cryopreservation presently justified? Hum Reprod 2004;19:14-9
58. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981;1:1132-4 (Pubitemid 11105800)
59. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-72
60. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004;19:1294-9 (Pubitemid 38807699)
61. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7
62. Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009;18:311-19
63. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010;122:803-11
64. Gerber B, Stehle H, Ricardo F, et al. ZORO: a prospective, randomized, multicentre study to prevent chemotherapy induced ovarian failure with the GnRH agonist gosereline in young hormone insensitive breast cancer patients receiving anthracycline containing (neo) adjuvant chemotherapy (GBG 37). J Clin Oncol 2009;27:15s A very important study. Controversial discussion on the ASCO 2010.
65. Del Mastro L, Boni L, Michelotti A, et al. GIM Group Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol (Meeting Abstracts) 2010;28:528 A very important study. Controversial discussion on the ASCO 2010.
66. Leonard RC, Adamson D, Anderson R, et al. The OPTION trial of adjuvant protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010;28(15 Suppl):abstract 590
67. Mastro LD, Levaggi A, Giraudi S, Pronzato P. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives. Cancer Treat Rev 2010. [Epub ahead of print]
68. ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update 2009;15:265-77
69. Chang SY, Soong YK. Unexpected pregnancies exposed to leuprolide acetate administered after the mid-luteal phase for ovarian stimulation. Hum Reprod 1995;10:204-6
70. Engel JB, Griesinger G, Schultze-Mosgau A, et al. GnRH agonists and antagonists in assisted reproduction: pregnancy rate. Reprod Biomed Online 2006;13:84-7 (Pubitemid 44054849)
71. Oliveira JB, Baruffi R, Petersen CG, et al. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol 2010;8:107
72. Bodri D, Sunkara SK, Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril 2010. [Epub ahead of print]
73. Cantineau AE, Cohlen BJ, Heineman MJ. Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility (Review). Cochrane Database Syst Rev 2007;(2):CD005356
74. Franco JG Jr, Baruffi RL, Mauri AL, et al. GnRH agonist versus GnRH antagonist in poor ovarian responders: a meta-analysis. Reprod Biomed Online 2006;13:618-27 (Pubitemid 44760884)
75. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception (Review). Cochrane Database Syst Rev 2006;(3):CD001750
76. Schultze-Mosgau A, Griesinger G, Altgassen C, et al. New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert Opin Investig Drugs 2005;14:1085-97 (Pubitemid 41246164)
77. Moghissi KS, Schlaff WD, Olive DL, et al. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 1998;69:1056-62 (Pubitemid 28274893)
78. Schlaff WD. Extending the treatment boundaries: zoladex and add-back. Intern J Gynecol Obstet 1999;64(Suppl 1):S25-31
79. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-62
80. Sisk CL, Zehr JL. Pubertal hormones organize the adolescent brain and behavior. Front Neuroendocrinol 2005;26:163-74 (Pubitemid 41772653)
81. Schweppe K. Endometriose: was tun- und wann? Frauenarzt 2003;44:739-44
82. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;20:2698-704
83. Wheeler JM, Malinak LR. Recurrent endometriosis: incidence, management, and prognosis. Am J Obstet Gynecol 1983;146:247-25
84. Rotondi M, Labriola D, Rotondi M, et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur J Gynaecol Oncol 2002;23:523-6 (Pubitemid 36069995)
85. Cobellis L, Razzi S, Fava A, et al. A danazol-loaded intrauterine device decreases dysmenorrheal, pelvic pain, and dyspareunia associated with endometriosis. Fertil Steril 2004;82:239-40 (Pubitemid 38968810)
86. Razzi S, Luisi S, Calonaci F, et al. Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril 2007;88:789-94 (Pubitemid 47498381)
87. Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? (Review). Curr Opin Obstet Gynecol 2010;22(4):283-8
88. Fuldeore MJ, Marx SE, Chwalisz K, et al. Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin 2010;26:729-36
89. Laufer MR. Current approaches to optimizing the treatment of endometriosis in adolescents. Gynecol Obstet Invest 2008;66(Suppl 1):19-27
90. Perez-Campos EF. Ethinylestradiol/dienogest in oral contraception. Drugs 2010;70:681-9
91. Vercellini P, Somigliana E, Vigano P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs 2009;69:649-75
92. Coddington CC, Grow DR, Ahmed MS, et al. Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial. Fertil Steril 2009;91:1909-13
93. Hurst BS, Matthews ML, Marshburn PB. Laparoscopic myomectomy for symptomatic uterine myomas. Fertil Steril 2005;83:1-23
94. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001;(2):CD000547
95. Compston JE, Yamaguchi K, Croucher PI, et al. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1995;16:261-7
96. West CP, Lumsden MA, Hillier H, et al. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Hum Reprod 1992;7:328-32
97. Morris EP, Rymer J, Robinson J, Fogelman I. Efficacy of tibolone as 'add-back therapy' in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil Steril 2008;89:421-8
98. Mizutani T, Sugihara A, Honma H, et al. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy. Gynecol Endocrinol 2005;20:80-3
99. National Vital Statistics Report, Available from: http://www.cdc.gov/ nchs/products/nvsr.htm [Last accessed 18th october 2010]
100. Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging 2009;4:259-67
101. Deeks ED. Histrelin: in advanced prostate cancer. Drugs 2010;70:623-30
102. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7
103. Informa-Pipeline, Available from: (http://informa-pipeline.citeline.com) [Last accessed 18 October 2010]
104. Citeline, Available from: (http://informa.citeline.com) [Last accessed 18 October 2010]
105. Chabre O, Conklin BR, Brandon S, et al. Coupling of the alpha 2A-adrenergic receptor to multiple G-proteins. A simple approach for estimating receptor-G-protein coupling efficiency in a transient expression system. J Biol Chem 1994;269:5730-4
106. Emons G, Kaufmann M, Gorchev G, et al. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol 2010;119:457-61
107. Bodri D, Sunkara SK, Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis (PubMed PMID: 20684954). Fertil Steril 2010. [Epub ahead of print]